155. EXPLORING LSD MICRODOSING IN AN OPEN-LABEL PILOT FOR MAJOR DEPRESSIVE DISORDER: THE INTERPLAY OF BEHAVIORAL ACTIVATION, MOOD IMPROVEMENT, AND CONNECTEDNESS
The International Journal of Neuropsychopharmacology August 1, 2025 C Donegan, D Daldagen-Bueno, Robin J Murphy et al.
Abstract Background Depressive disorders affect about 280 million people worldwide, with many struggling to find effective relief. Conventional antidepressants are widely prescribed but often lack efficacy and have side effects, leaving many patients dissatisfied or untreated. Concurrently, psychedelic therapies have gained momentum in both research and ‘in the wild’, with emerging evidence...